Podcasts about Medtronic

Former White House AI and Crypto Czar David Sacks joins to discuss data centers, AI and regulation. Then, Medtronic CEO Geoff Martha breaks down the company's latest quarter and discusses their big bet on robotics surgery. Plus, Needham analyst Laura Martin grades Tim Cook's tenure at Apple as new CEO John Ternus takes the helm today. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

You don't just carry the weight of your past; you choose how to carry it forward. Reclaiming your power starts the moment you reframe "I have to" into "I choose to." This week, host Peter Fenger welcomes Larry Freeborg, a veteran corporate marketing leader at 3M and Medtronic, master transformation coach, and author of the deeply impactful new book, Always At Choice. Following a period of heartbreaking grief and loss early in his life, Larry has spent forty years guiding leaders and individuals through their critical pivot points to find both career success and internal alignment. Now 87, Larry embodies his commitment to lifelong learning, demonstrating that hard circumstances never strip away our ultimate agency. Tune in for an inspiring conversation on moving from survival mode to purposeful living, using Larry's framework to turn trial into strength.   For more information about “Always At Choice” by Larry Freeborg, please visit: https://alwaysatchoice.net For more information about Stepping Through the Gate, please visit: https://steppingthroughthegate.com For more information about Larry Freeborg, please visit: https://alwaysatchoice.net/about Connect with Larry on social media: On Instagram: https://www.instagram.com/freeborglarry/ On Linkedin: https://www.linkedin.com/in/larry-freeborg/ On Facebook: https://www.facebook.com/people/Larry-Freeborg-Author/61583952046042/

Freddie sits down with Peter Simonson — a Georgia Tech-trained mechanical engineer who invented Medtronic's TSRH-3D spinal implant system before turning his focus to bone health as President and Co-Founder of Juvent — for a deep dive into micro-impact therapy and why bone may be the most overlooked organ system in longevity conversations. Peter walks through the history of vitamin discovery, starting with scurvy and vitamin C, as a framework for understanding micro-impact as a daily mechanical requirement rather than a treatment for any single condition. From there, the conversation moves into the engineering itself: why the Juvent Micro-Impact Platform® is capped at 0.3G, how frequency and load are two entirely different safety variables, and why a body of vibration-safety literature exists in occupational safety research that most clinicians have never encountered. Peter also references a study conducted at St. Jude on bone density outcomes in pediatric transplant patients, and the two share personal family stories — Freddie's mother and Peter's mother — about osteoporosis and mobility later in life. Note: this conversation covers emerging research and technology. Some figures and studies mentioned reflect the guest's own citations and firsthand experience shared in conversation. Peak Moments 0:00 – Intro: morning routine and setting up the conversation 1:18 – What is Juvent? Defining the category 1:57 – The scurvy & vitamin C history lesson 5:48 – Why micro-impact is a daily requirement, not a treatment 10:03 – What's actually inside the Juvent platform 11:15 – Why 0.3G — the bone science behind low-load, high-frequency 12:42 – Walking vs. jackhammer: the frequency/impact analogy 13:48 – The porcine brain study and "Faraday spikes" 15:33 – The hidden body of occupational vibration-safety literature 17:21 – Lawsuits, white papers & tearing apart a competitor's "rock shaker" plate 19:00 – Resonance explained: the swing, the wine glass, and personalized frequency scanning 23:20 – Origin story: Jack Ribey and the technology's early history 25:52 – Freddie's mom's pelvic fracture recovery story 28:20 – Bone as a metabolic and endocrine organ 33:12 – The economics of nursing homes, and Peter's mom's osteoporosis story 39:18 – The rodent study on stem cells and bone density 41:59 – The St. Jude study: bone density outcomes 45:25 – Buffalo Bills' Eric Wood and career longevity 48:20 – Biohacking vs. medical world: how RCTs actually work 53:20 – Lymphatic drainage: Juvent's secondary mechanism 58:12 – Quickfire: addressing deficiencies before treatment 1:03:37 – The two fundamentals: deficiency and toxin removal 1:07:10 – Peter's two walking life hacks 1:09:02 – Juvent discount code & buyback guarantee 1:11:16 – Newton's law: the quick safety litmus test 1:12:05 – Where to find Juvent + closing thoughts Connect with Peter: https://www.linkedin.com/in/peter-simonson-330443b/ Get Juvent: https://www.juvent.com/?ref=pugsstmo Use Code Beautifully broken Upgrade Your Wellness: LightPathLED Red Light Therapy: https://bit.ly/4gwYiUh Code: beautifullybroken Explore Aurawell PEMF and Magnawave: https://calendly.com/freddiekimmel/let-s-conect-clone Silver Biotics Wound Healing Gel: https://bit.ly/3JnxyDD 30% off with Code: BEAUTIFULLYBROKEN MaxGen Labs: https://maxgenlabs.com/BEAUTIFULLYBROKEN CONNECT WITH FREDDIEWork with Me: https://www.beautifullybroken.world/biological-blueprintWebsite and Store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/freddie.kimmelYouTube: https://www.youtube.com/@beautifullybrokenworld Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Medsider Radio, we sat down with Deanna Harshbarger, CEO of Cala Health.Cala Health developed the Cala kIQ® System, a prescription wearable therapy for action hand tremor.Deanna holds a degree in chemical engineering and brings more than 20 years of commercial medtech experience to Cala. Before joining the company, she held senior leadership roles at Johnson & Johnson, Boston Scientific, and Medtronic, and helped develop and commercialize technologies across interventional cardiology, neuromodulation, and diabetes care.In this conversation, Deanna shares how she empowers leadership teams to execute, building clinical evidence step-by-step, how patient observation shapes product development, and why raising capital is both a sprint and a marathon.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Deanna Harshbarger, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:34) - Deanna's journey from J&J, Boston Scientific, and Medtronic to Cala Health (08:16) - How Cala personalized therapy around each patient's unique experience (11:53) - Operating lessons Deanna carried from strategics to startups (22:27) - The unboxing interview that changed Cala's product design (29:16) - How Cala balanced feasibility studies, RCTs, and real-world evidence after its commercial launch (34:33) - Years of clinical evidence helped Cala win reimbursement for a new therapy (38:52) - The case for holding back when you're ready to commercialize (44:30) - Why fundraising is both a sprint and a marathon

How surgical devices are cleaned and decontaminated determines the efficacy of the sterilization process. For this to be effective, each item must be cleaned according to its instructions for use (IFU). But, how do manufacturers validate cleaning processes for their instruments? In episode 157, host Casey Czarnowski speaks with Dr. William Levia of Medtronic about the manufacturer validation process. Dr. Levia describes the many detailed steps that manufacturers must go through to test cleaning protocols and the reasons behind them. He refers to the different classes of medical devices and discusses the roles of regulatory agencies, standards-setting organizations and testing laboratories. He also introduces listeners to ANSI/AAMI ST98:2022 Cleaning validation of health care products—Requirements for development and validation of a cleaning process for medical devices. Dr. Levia believes in bridging “the standards, the core science and the real-world setting.” Listen to learn more about how instrument manufacturers do their jobs, so we can do ours. ABOUT OUR GUEST Dr. William Levia Global Senior Program Manager for Sterile Processing Medtronic Dr. William Leiva received his PhD in Cybernetics and Statistics from Bucharest University of Economic Studies in 2024 and his MPH in Epidemiology and Health Economics from Andrés Bello National University in 2018. He has worked as a Senior Manager for Scientific Affairs at 3M Healthcare (2008–2023), sterilization and reprocessing subject matter expert at the FDA, and in a leadership role at Medtronic since 2024. He also holds a visiting professorship at Bucharest University of Economic Studies. Dr. Leiva is a recipient of AAMI's Kilmer Grant, serves as a reviewer of peer-reviewed articles, and has presented internationally, including at AAMI eXchange and WFHSS. His research topics include reusable medical device decontamination, terminal sterilization, sterile barrier systems and reprocessing economic epidemiology.   Earn CE Now

In this episode of The Lead recorded at EHRA, host Christopher Kowalewski, MD, is joined by Tina Baykaner, MD, MPH, and Sanjiv M. Narayan, MD, PhD, FHRS, to discuss the journal article, Relationship Between Time-to-First Atrial Tachyarrhythmia Recurrence and Atrial Fibrillation Burden: Implications for Trial Design. Together, they examine the relationship between time to first atrial tachyarrhythmia recurrence and atrial fibrillation burden and discuss the implications of these measures for clinical trial design. Learning Objectives Review the relationship between time-to-first atrial tachyarrhythmia recurrence and atrial fibrillation burden. Discuss how different measures of atrial fibrillation recurrence and burden may influence the interpretation of clinical trial outcomes. Examine the implications of atrial fibrillation burden and time-to-first recurrence for the design of future atrial fibrillation trials.   Host: Christopher Kowalewski, MD   Guests: Tina Baykaner, MD, MPH and Sanjiv M. Narayan, MD, PhD, FHRS   Disclosures:   C. Kowalewski No relevant disclosures   T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific   S. Narayan Honoraria/Speaking/Consulting Fee: UpToDate, Inc, LifeSignals, Abbott Medical, TDK Inc. Research: National Institutes for Health Intellectual Property Rights: University of California Regents Stocks – Privately Held: Physcade

In this episode of the Medical Sales Podcast, host Samuel Adeyinka sits down with Jaymen McClain, a Senior Cardiac Rhythm Management Sales Rep at Medtronic, to take listeners inside the fast-paced world of cardiac medical device sales. Jaymen shares what a typical day looks like, from supporting pacemaker and ICD implants to working alongside electrophysiologists and cardiologists, managing a team of clinical specialists, and responding to urgent cases. He also breaks down how to build trust with physicians, win business against long-standing competitors, become a valuable resource in the procedure room, and navigate the unpredictable on-call lifestyle. Jaymen also discusses compensation, career growth, burnout, work-life balance, and the persistence it took to transition from pharmaceutical sales into medical devices. This episode is a must listen for anyone considering a career in cardiac medical device sales or looking to become a top-performing medical sales rep. Connect with Jaymen McClain: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »

Violoniste, artiste engagée, auteure, Esther Abrami s'est imposée comme l'une des figures incontournables de la nouvelle génération de musiciennes classiques.Mais derrière la virtuosité et la lumière de la scène se trouve une histoire profondément liée à la transmission : celle d'un violon reçu à l'âge de trois ans, hérité de sa grand-mère et chargé d'une mémoire familiale qui allait faire naître une vocation.La transmission, thématique de cette cinquième édition des Legend Ladies Nights, c'est précisément cela : recevoir une histoire, se l'approprier, la transformer, puis choisir ce que l'on souhaite en faire vivre.Dans cette conversation, Esther Abrami raconte le travail, les sacrifices et les obstacles nécessaires pour transformer un rêve d'enfant en réalité. Elle évoque aussi les préjugés auxquels les femmes restent confrontées dans l'univers de la musique classique et la difficulté de s'autoriser lorsque celles qui nous ont précédées ont été effacées des récits.Transmettre, c'est alors faire vivre un héritage, mais aussi réparer certains oublis. À travers son travail, elle redonne ainsi une voix et une place à des compositrices longtemps invisibilisées.Ce faisant, c'est aussi permettre à une nouvelle génération de petites filles de monter sur scène en sachant qu'elles y ont toute leur place.Une conversation sensible et inspirante sur la vocation, la mémoire, la légitimité, la place des femmes dans l'histoire de la musique et ce que nous choisissons, à notre tour, de transmettre.Cette 5ème édition des Legend Ladies Nights a été rendue possible grâce au précieux soutien de nos partenaires : Medtronic, Mastercard, Release Capital et Mediawan.

Larry Patterson went in for a routine hernia repair. He came out, eventually, with several inches of his bowel removed. Timothy O'Brien, board-certified trial attorney and shareholder at Levin Papantonio, just won $88 million for Patterson and his wife Tammy against Covidien, a Medtronic company. It is the largest compensatory award in fifteen years of mesh litigation, and the first of roughly 2,500 cases to reach a jury. The mesh, Symbotex, sits right against your intestines behind a collagen barrier meant to last 30 days. Covidien's own internal testing showed it was gone in under seven. They knew in 2003. O'Brien walks Gregg through the evidence that turned the trial, where sales staff swore to doctors the barrier lasted a month while R&D said otherwise in writing. He also maps the hernia mesh lawsuit landscape, from the Bard settlement covering 33,000 claimants to why Medtronic Covidien is the last major manufacturer still fighting, and what a bellwether verdict actually means for the thousands of people still waiting on their own cases   Join Gregg and Timothy O'Brien on Climate Change Environment Science & the Law as they explore:   What You'll Learn Why a generation of surgeons stopped doing tissue-to-tissue repair, and what that traded away How Symbotex's protective barrier was supposed to work, and how fast it actually disappeared The 2003 document that locked in the depositions and became the case's spine Why sales and R&D were telling two completely different stories about the same product What a bellwether trial is, and why the first one carries the most weight Where the Bard, Johnson & Johnson, and Medtronic Covidien litigations stand right now Why about 100 new Covidien cases are still being filed every month What Covidien's planned appeal means for people still waiting How to find out if you or someone you love has a case   Time Stamps 0:00 – "They are lying": the sales pitch vs. the truth 0:48 – Meet attorney Timothy O'Brien 1:02 – The hernia mesh "safety feature" that failed 2:06 – Why hernia mesh exists in the first place 4:13 – The Patterson case: what happened to the plaintiff 5:41 – The depositions that exposed Covidien 7:46 – 2003: when they allegedly knew the truth 9:33 – The 3 major mesh manufacturers, explained 11:59 – What a "bellwether trial" means for your case 14:07 – Will Covidien settle or appeal? 17:40 – How to contact Timothy O'Brien about your case   Timothy O'Brien is a board-certified trial attorney and shareholder at Levin Papantonio, where he has served as lead or co-lead counsel in mass tort litigation against major hernia mesh manufacturers, including Bard, Johnson & Johnson, and Medtronic Covidien. He recently helped secure an $88 million verdict in the first bellwether trial of the Covidien hernia mesh multidistrict litigation.    Contact / Follow Timothy O'Brien:  Firm: Levin Papantonio  Website: https://levinlaw.com     Want more conversations that cut through the noise on science, climate, and the issues shaping our future? Subscribe to Climate Change Environment Science & the Law with Gregg Goldfarb for new episodes every week.   

Saul Marquez is a prominent figure in healthcare digital marketing, serving as the founder and CEO of Outcomes Rocket, a global digital marketing agency serving healthcare clients exclusively. With over twenty years of experience in sales and marketing within the healthcare sector, Saul's journey began in sales and leadership roles at major players like Stryker, NuVasive, and Medtronic. Recognizing significant gaps that companies were faced with in strategy, digital marketing, and commercialization during his career, Saul established Outcomes Rocket to address these challenges head-on. The consultancy focuses on helping healthcare brands and businesses scale and thrive in the digital age.

In this episode of The Lead recorded at HRS2026, host Danesh Kella, MBBS, FHRS is joined by Jeffrey S. Healey, MD, FHRS and Fred M. Kusumoto, MD, FHRS to discuss the journal article, Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation (The CLOSURE-AF Trial). Together, they review the study findings comparing left atrial appendage closure with medical therapy in patients with atrial fibrillation and discuss the potential implications for clinical practice. Learning Objectives Review the design and key findings of the CLOSURE-AF Trial comparing left atrial appendage closure with medical therapy in patients with atrial fibrillation. Discuss the comparative considerations of left atrial appendage closure and medical therapy for the management of atrial fibrillation. Examine the potential clinical implications of the CLOSURE-AF Trial for treatment decision-making in patients with atrial fibrillation.   Host: Danesh Kella, MBBS, FHRS Guests: Jeffrey S. Healey, MD, FHRS and Fred M. Kusumoto, MD, FHRS   Disclosures: D. Kella Honoraria/Speaking/Consulting Fee: Zoll Medical Corporation, MBW Spectrum   J. Healey Honoraria/Speaking/Consulting Fee: Boston Scientific, Servier Research: Pfizer, Boston Scientific, Medtronic, Inc. Speakers' Bureau: Bristol-Myers Squibb   F. Kusumoto No relevant disclosures

Dr. Austin Chiang has built one of medicine's most distinctive public platforms. He is a triple board-certified gastroenterologist, Chief Medical Officer for Medtronic's Endoscopy business and Associate Professor of Medicine at Thomas Jefferson University. He is also one of healthcare's most influential physician voices online, with hundreds of thousands of followers across TikTok, Instagram, YouTube and LinkedIn. That makes him an ideal guest for Season 11 of Fixing Healthcare with cohosts Dr. Robert Pearl and Jeremy Corr. This season asks what patients, clinicians and healthcare leaders are saying now that feels meaningfully different from the past. Chiang hears those concerns from several vantage points: as a practicing physician, medical technology leader, educator and public-facing doctor. For Chiang, three issues stand out: Clinician burnout and loss of autonomy Chiang says physicians are struggling with administrative burden, documentation demands, prior authorization, staffing shortages, reimbursement pressure and a growing sense that medical decisions are no longer fully in their hands. Pearl pushes further, asking whether clinicians must take more responsibility for affordability rather than simply objecting to the oversight created in response to rising costs. Chiang agrees that physicians need a better understanding of the broader healthcare ecosystem if they want to help change it. Medical misinformation and social media Chiang has spent more than a decade learning how to communicate across platforms and audiences. He explains that accurate medical information must now compete with sensationalized claims from people who are not held to the same professional standards as clinicians. For doctors, the challenge is to be credible without being boring, engaging without becoming irresponsible and platform-specific without compromising the message. That tension is especially important in areas like gut health, diet, probiotics and the microbiome, where uncertainty creates space for simple but potentially misleading answers. Clinician-led innovation As Medtronic's Chief Medical Officer for Endoscopy, Chiang works at the intersection of clinical practice and medical technology. He explains that innovation in medicine is slow for good reason: new tools must prove safety, clinical value, workflow fit and real-world usefulness before becoming mainstream. But he argues that clinicians need to be more involved in that process because they understand the nuances of patient care, staff experience and adoption better than outsiders can. The conversation also explores colorectal cancer, which is rising among younger adults. Chiang explains why colonoscopy remains the gold standard for prevention, while also noting that lowering screening ages further would create major capacity challenges. He also discusses AI-assisted polyp detection, the future of endoscopy and why fully autonomous colonoscopy remains difficult given the complexity of human anatomy. There's much more in this conversation, including physician career paths beyond traditional practice, how doctors should respond when patients bring AI-generated information to appointments and what people with chronic GI conditions need from clinicians, platforms and online communities. Tune in to hear one of medicine's most visible digital physician leaders explain how doctors can help shape a future where technology, social media and medical innovation better serve patients. * * * Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple, Spotify, Stitcher or wherever you find podcasts. Join the conversation or suggest a guest by following the show on X and LinkedIn. The post FHC #224: Austin Chiang on burnout, misinformation and the future of med-tech appeared first on Fixing Healthcare.

Urge urinary incontinence (UUI) places a significant emotional and physical burden on women affected. Sacral neuromodulation has been and remains a well-established implant-based therapy for UUI. The concept originated in the early 1970s from sacral anterior root stimulation research for neurogenic bladder, with human clinical trials beginning in 1982. Medtronic's InterStim device received FDA approval in 1997 for UUI, and in 1999 for urgency-frequency and nonobstructive urinary retention. This was a game changer for affected women. Now, as of August 5, 2026, the FDA has granted 510(k) clearance for a new, less invasive neuromodulation implant- placed in the ANKLE. This is the Revi Extend Implant system (BlueWind Medical). What was the phase 3 data on this? What does the “wearable controller device” look like? Listen in for details. 1. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary Incontinence in Women: A Review. JAMA. 2017;318(16):1592–1604. doi:10.1001/jama.2017.121372. Amundsen CL, Sutherland SE, Heesakkers JPFA, et al. Three-year efficacy and safety of Revi implantable tibial neuromodulation from the pivotal OASIS study. J Urol. 2026;216(2):219-229. doi:10.1097/JU.00000000000050623. BlueWind Medical receives FDA 510(k) clearance for Revi Extend implant. News release. BlueWind Medical Ltd. August 5, 2026. Accessed August 5, 2026. https://www.businesswire.com/news/home/20260805290667/en/BlueWind-Medical-Receives-FDA-510k-Clearance-for-Revi-Extend-Implant

In this episode, we are discussing one of the most rapidly evolving areas in acute stroke care, mechanical thrombectomy for medium vessel occlusions, or MEVO. While thrombectomy is well established for large vessel occlusions, whether patients with smaller, more distal occlusions benefit has remained an important unanswered question. In the recent years, several landmark trials have evaluated endovascular treatment for MEVO with differing results, some suggesting benefits while others suggesting no benefit. Together, these studies have shifted the conversation from whether thrombectomy should be performed to which patients are most likely to benefit. To discuss how these findings are reshaping clinical practice and the future of thrombectomy stroke trials, we spoke with Dr. Mayank Goyal, professor of radiology and clinical neurosciences at the University of Calgary. He was interviewed by Dr. Omar Al-Janabi, a stroke neurologist at Baptist Health.    Disclosures: Dr. Goyal discloses consulting fees from Medtronic, Penumbra, Jacob's Institute, Silvercreek Pharma, Microvention, and grant funding from Medtronic and Cerenovus

Advanced patient monitoring becomes more practical for ASCs when innovation is integrated, scalable, and built around real outpatient workflows. In this episode, Blake Tatum, Vice President of US Commercial for Medtronic Acute Care and Monitoring, and Mike Lessick, Vice President of Sales and Marketing, Patient Monitoring, and Life Support for Mindray North America, discuss how their expanded partnership is helping ambulatory surgery centers access hospital-level monitoring technology in a simpler, more affordable way. They explain how Medtronic technologies, including Nellcor™ SpO2 monitoring, Microstream™ capnography, BIS™ brain monitoring, and INVOS™ tissue oximetry, can be integrated into Mindray's ASC-focused monitoring platform. Blake highlights how the partnership reduces complexity, enables faster access to innovation, and provides ASCs with flexible options to scale technology over time. Mike shares how a single integrated platform can reduce cognitive load for clinicians, streamline purchasing and training, and support stronger connectivity with electronic medical records. Tune in to learn how integrated monitoring partnerships can help ASCs improve efficiency, support clinical quality, and prepare for the next wave of outpatient care. Resources: Connect with and follow Blake Tatum on LinkedIn. Follow Medtronic on LinkedIn and discover their website! Follow and connect with Michael Lessick on LinkedIn. Follow Mindray on LinkedIn and discover their website!

Episode 29: Treating Teen Obesity: A National Leader in Bariatric Surgery on GLP-1 vs. Surgery https://cmetracker.net/UTHSCSA/Publisher?page=pubOpen#/getCertificate/10103150     FACULTY: Richard Peterson, MD is a Professor and serves as the Chief of Bariatric and Metabolic Surgery for UT Health San Antonio and is the medical director of the Christus Weight Loss Institute at Westover Hills.   OVERVIEW: Host Holly Wayment sits down with Dr. Richard Peterson to unpack the shifting landscape of pediatric obesity care. Dr. Peterson explains why GLP-1 medications have driven down bariatric surgery volumes — and why surgery still offers the most durable outcomes for obesity and its complications. He walks through updated pediatric referral criteria, compares results across medication and surgical pathways, and outlines when a combined or individualized approach makes the most sense.   For pediatricians, the takeaways are practical: recognize obesity as a disease, partner with obesity specialists, navigate insurance and access barriers, and intervene early to improve long-term outcomes for adolescents and their families.   The American Academy of Pediatrics released updated obesity guidelines in 2023 that moved away from the old “watchful waiting” approach. Under the new guidance, providers should offer weight-loss medications to patients age 12 and older with obesity, alongside lifestyle treatment, and patients 13 and older with severe obesity should be evaluated for bariatric surgery. Severe obesity is defined as a BMI at or above 120% of the 95th percentile for age and sex. Medication isn't meant to be a first-line or standalone treatment — the AAP still supports intensive health behavior and lifestyle treatment as the initial step in pediatric weight management. In a follow-up policy statement, the AAP called severe pediatric obesity an “epidemic within an epidemic” and urged that insurance cover surgery and follow-up care at high-quality multidisciplinary centers.   OVERALL LEARNING OBJECTIVE: Increased awareness and education for pediatric providers   DISCLOSURE TO LEARNERS: Speaker: Richard Peterson, MD has disclosed he is a consultant for Teleflex/Standard Bariatrics, Medtronic, and Intuitive. The relevant financial relationships noted for Dr. Peterson have been mitigated.        The Pediatrics Now Podcast Planning Committee members: Steven Seidner, MD, and Holly Wayment have no relevant financial relationships with ineligible companies to disclose.   The University of Texas at San Antonio and Steven Seidner, MD course director and content reviewer for the activity, have reviewed all financial disclosure information for all speakers, facilitators, and planning committee members; and determined and resolved all conflicts of interests. CONTINUING MEDICAL EDUCATION STATEMENTS: The University of Texas at San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Texas at San Antonio designates this live activity up to a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CERTIFICATE OF ATTENDANCE: Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance. Credit may be obtained upon successful completion of the activity's evaluation. RELEASE DATE: 8/12/2026 EXPIRATION DATE: 8/31/2028  

Recording of the EA26 Innovation Talk sponsored by Medtronic, Philips, and Tuoren ESAIC Expert and Chair: Wolfgang Buhre (the Netherlands)Speakers (Industry representatives):Zaza Iakobishvili (Israel) — MedtronicMark-Holger Konrad (Germany) — PhilipsMing Tian (China) — Tuoren

Recording of the EA26 Innovation Talk sponsored by Masimo, Medtronic, and smartQare ESAIC Expert and Chair: Joana Berger-Estilita (Switzerland)Speakers (Industry representatives):Akira-Sebastian Poncette (Germany) — MasimoOsama Abou Arab (France) — MedtronicWalter van Kuijen (the Netherlands) — smartQare

July 2026 Sustainable Stock and ETF Picks. Includes articles on the top sustainable pharmaceutical companies, clean energy ETFs, and more! By Ron Robins, MBA Transcript & Links, Episode 169, July 31, 2026 Hello, Ron Robins here. Welcome to my podcast episode 169, published on July 31, 2026, titled "July 2026 Sustainable Stock and ETF Picks." Now, before I begin, I want to apologize if my voice at any time sounds a little rough! This podcast is presented by Investing for the Soul. Investingforthesoul.com is your go-to site for vital global, ethical, and sustainable investing mentoring, news, commentary, information, and resources. Remember that you can find a full transcript and links to content, including stock symbols and bonus material, on this episode's podcast page at investingforthesoul.com/podcasts. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, and I don't receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal any investments I have in the investments mentioned herein. I have a terrific crop of 27 articles for you in this podcast! Note: Sometimes companies are covered more than once. Now with so many articles to potentially cover, I've chosen 4 to quote from. Titles and links to the other 23 can be found on the webpage for this podcast edition. ------------------------------------------------------------- 1) Top 10: Sustainable Pharmaceutical Companies from sustainabilitymag.com I'm beginning this podcast with an article that reviews an industry that is controversial for some ethical and sustainable investors. Nonetheless, the sponsor of this industry analysis needs to be considered. The title of the article is: Top 10: Sustainable Pharmaceutical Companies from sustainabilitymag.com. It's by David Weston. Here is some of his analysis. "Here we present the pharmaceutical companies leading in corporate responsibility, innovation and dedication to a healthier, increasingly sustainable future. 10. Boston Scientific (BSX) Founded: 1979 HQ: Marlborough, US Net Zero Target: 2050 In the short term, it aims to achieve a 46.2% absolute reduction in Scope 1 and 2 emissions by 2030 – compared to a 2019 baseline. By 2050, it wants to achieve a 90% absolute reduction. 9. UnitedHealth Group (UNH) Founded: 1974 HQ: Eden Prairie, US Net Zero Target: 2050 UnitedHealth Group is working to source 100% of its energy from renewable sources and reduce Scope 1 and 2 emissions by 60% by 2030. 8. Danaher (DHR) Founded:1969 HQ: Washington, DC, US Net Zero Target: 2050 Danaher's 2025 Scope 1 and 2 emissions were 30% lower than the 2021 baseline, with 70% of the electricity consumed in its operations drawn from renewable sources. 7. Elevance (ELV) Founded: 1944 HQ: Indianapolis, US Net Zero Target: 2030 Elevance Health… uses 100% renewable electricity, and encourages suppliers to adopt science-based targets… Its initiatives include energy and water efficiency, responsible waste management and low-carbon commuting. 6. Medtronic (MDT) Founded: 1949 HQ: Minneapolis, US Net Zero Target: 2045 Medtronic aims to have 75% of its suppliers backed by science-based targets by 2030… Medtronic also wants to reduce absolute Scope 1 and 2 GHG emissions 52% by FY30 from a 2020 base year. Top 5... 5. McKesson (MCK) Founded: 1833 HQ: Irving, US Net Zero Target: Reduce direct GHG emissions by 50% by 2032. It aims to reduce direct GHG emissions by 50% by 2032 from a 2020 base year. 4. Bayer (BAYN) Founded: 1863 HQ: Leverkusen, Germany Net Zero Target: Before 2050 By the end of 2029, it targets a 42% reduction in Scope 1 and 2 emissions from a 2019 baseline. Strategies include… transitioning to 100% renewable electricity. 3. CVS Health (CVS) Founded: 1963 HQ: Woonsocket, US Net Zero Target: 2050 In 2021, CVS Health emerged as a global leader by securing SBTi validation for its net zero targets… The company is targeting 50% renewable electricity by 2040. 2. Haleon (H6G.SG) Founded: 2022 HQ: Weybridge, UK Net Zero Target: 2040 Haleon uses 100% renewable electricity across its production facilities. 1. Thermo Fisher Scientific (TN8.F) Founded: 2006 HQ: Waltham, US Net Zero Target: 2050 Thermo Fisher Scientific… interim targets including a 50% reduction in greenhouse gas emissions from 2018 levels and 80% renewable energy use by 2030." End quotes. ------------------------------------------------------------- 2) Riding the Green Wave: Clean Energy ETFs Benefiting from etftrends.com Now the case for green energy is clearer than ever, and this article offers reasons for it and what investments to look at. It's titled Riding the Green Wave: Clean Energy ETFs Benefiting from etftrends.com. It's by Ryan Schloesser, and here are some quotes from his article. "Following a multi-year slump in clean energy ETF performance, geopolitical tensions sparking global energy security concerns and energy demand from AI data center projects have driven clean energy investment in 2026… (Starting with) Gains in (3) Global Clean Energy (ETFs) 1. iShares Global Clean Energy ETF (ICLN) tracks the performance of the S&P Global Clean Energy Index… (The) iShares Global Clean Energy ETF has climbed over 20%, and has received inflows of $507 million so far in 2026. 2. Fidelity Clean Energy ETF (FRNW) tracks the Fidelity Clean Energy Index, targeting global companies that derive at least 50% of their revenues from renewable energy. The fund has seen a return of 17.3% and inflows of $60 million this year.  3. Invesco Global Clean Energy ETF (PBD) follows the performance of the WilderHill New Energy Global Innovation Index… (The) Invesco Global Clean Energy ETF has climbed 19% and recorded inflows of $6.5 million in 2026.  Capturing the North American Energy Shift (are the following 4 funds) 1. Invesco WilderHill Clean Energy ETF (PBW) tracks the WilderHill Clean Energy Index… The fund has climbed 20.6% this year with outflows of -$305.2 million as surging Treasury yields and potential interest rate hikes pressure smaller-cap holdings.  2. First Trust NASDAQ Clean Edge Green Energy Index Fund (QCLN) tracks the NASDAQ Clean Edge Green Energy Index targeting North American companies across the green value chain… The fund has grown 27.2% this year and received inflows of $110 million.  3. ALPS Clean Energy ETF (ACES) and 4. (the) ALPS Electrification Infrastructure ETF (ELFY) both provide North American exposure to the clean energy sector. (The) ALPS Clean Energy ETF tracks the CIBC Atlas Clean Energy Index… Focusing more on the electrification infrastructure component of the clean energy transition, (the) ALPS Electrification Infrastructure ETF tracks the Ladenburg Thalmann Electrification Infrastructure Index, providing exposure to the companies physically supplying electricity and grid infrastructure. This year, the funds have returned 5.4% and 22.7%, with inflows of $12.8 million and $58.6 million, respectively.  (And 2) Pure Play (Funds with) Exposure to Solar and Wind 1. Invesco Solar ETF (TAN) offers concentrated exposure to a portfolio of companies involved in the global solar value chain by tracking the MAC Global Solar Energy Index. 2. First Trust Global Wind Energy ETF (FAN) tracks the ISE Clean Edge Global Wind Energy Index. (The) Invesco Solar ETF has returned 14.7% with inflows of $536.1 million in 2026, while (the) First Trust Global Wind Energy ETF has risen 21.8% and recorded inflows of $62.8 million over the same period." End quotes. ------------------------------------------------------------- 3) 3 AI Infrastructure Stocks That Could Double by 2027 from finance.yahoo.com Many ethical and sustainable investors are heavily invested in the AI sphere. So as an homage to them, I have this recent article titled 3 AI Infrastructure Stocks That Could Double by 2027 from finance.yahoo.com. It's by Will Healy at fool.com. Here's a bit of what he says in his article. "1. Nvidia (NVDA) trades at a P/E ratio of 31, which is actually less than the S&P 500 average of 32. This has occurred as Nvidia's revenue grew by 85% yearly in the first quarter of fiscal 2027 (ended April 26). When also considering the 211% profit increase for the same period, the earnings multiple would arguably appear low even if Nvidia's stock price were to double. 2. CoreWeave (CRWV) As one of the leading neocloud companies, CoreWeave has drawn increased attention. Amid the potential for massive stock gains, huge losses and rapidly rising debt levels have soured some investors on this company… CoreWeave has Nvidia as an investor and a partner. That gives the company capital and access to Nvidia's latest technology, giving CoreWeave a competitive advantage. 3. Meta Platforms (META) Facebook parent Meta Platforms is in the process of transitioning into more of an AI-oriented enterprise. The company pledged to spend between $125 billion and $145 billion in capital expenditures (capex), most of which will probably go to building more AI infrastructure… Indeed, the 26% forecasted revenue increase for 2026 is a slowdown from Q1. Nonetheless, that would put downward pressure on an already low P/E ratio if the stock price stayed the same. Moreover, if Meta's AI inspired more confidence, its current valuation indicates the stock price could double without making Meta an expensive stock." End quotes. ------------------------------------------------------------- 4) Top Wind Energy Stocks to Add to Your Portfolio for Solid Long-Term Returns -- from Zacks.com Lastly, I have this article covering a sector that most of you are concerned with. It's titled Top Wind Energy Stocks to Add to Your Portfolio for Solid Long-Term Returns -- from Zacks.com. It's by Avisekh Bhattacharjee. Here are some quotes from his article. "(Note that this is) an updated edition of the May 28, 2026 article. 1. NextEra Energy (NEE - Free Report) is a public utility holding company engaged in the generation, transmission, distribution and sale of electric energy. The Zacks Rank #2 (Buy) company's competitive energy business, NextEra Energy Resources LLC ('NEER'), is a leading generator of wind energy globally. 2. Duke Energy (DUK - Free Report) is a premier utility service provider offering efficient power and energy services. The Zacks Rank #2 company is currently focused on expanding its scale of operations, implementing modern technologies at its facilities as well as enhancing its renewable generation portfolio by investing heavily in infrastructure and expansion projects. 3. American Electric Power (AEP - Free Report) is a public utility holding company, which, through directly and indirectly owned subsidiaries, generates and transmits electricity. Wind forms a part of the company's broader strategy to diversify its generation portfolio and lower carbon emissions… The Zacks Rank #2 company is expanding its regulated renewable asset base. 4. Vestas Wind Systems (VWDRY - Free Report) is a renowned designer, manufacturer, installer and service provider for wind turbines across the globe. To capitalize on rising demand for renewable power, the company emphasizes wind capacity expansion, technological advancement and sustainable energy development… In June 2026, the Zacks Rank #2 company secured five new orders to deliver wind turbines in Germany." End quotes. ------------------------------------------------------------- 23 more articles from around the world with Sustainable Investment Picks for July 2026. 1. Title: This Solar Power Stock Still Has a Bright Future from barrons.com. By Avi Salzman. 2. Title: Solar Beats Coal for the First Time: 3 Dividend Stocks to Buy Now from fool.com. By Reuben Gregg Brewer. 3. Title: 3 Consumer Staples Stocks Riding The Fairtrade Spending Trend from simplywall.st. Reviewed by Sasha Jovanovic. 4. Title: 1 Nvidia-Backed AI Infrastructure Stock to Buy Hand Over Fist Right Now from fool.com. By Dave Kovaleski. 5. Title: Top 10: Wind Power Companies from energydigital.com. By James Darley. 6. Title: This AI Infrastructure Company Has a $638 Billion Backlog and Is Trading Near an 18-Month Low from fool.com. By Matt Frankel, CFP®. 7. Title: 3 Green Investment Stocks Backed By Copper, Biofuels And Solar Demand from simplywall.st. Reviewed by Sasha Jovanovic. 8. Title: Forget Nvidia: This Infrastructure Upstart Is The Real Backdoor AI Winner from fool.com. By Leo Sun. 9. Title: 3 Stocks to Buy on the AI Infrastructure Sell-Off from fool.com. By Geoffrey Seiler. 10. Title: This ESG ETF Owns Google and Intel but Won't Touch Meta, and It's Up 22% in a Year from finance.yahoo.com. By Michael Williams at 24/7 Wall St. Continuing 12. Title: 3 Alternative Energy Stocks Investors Are Watching After The Oil Shock from simplywall.st/. By Sasha Jovanovic. 13. Title: ENVX Stock Soars at Yahoo: Is This the Next Big Environmental Investment?! From catalogo.cpal.edu.pe/. By CPAL. 14. Title: Buy 3 High-Flying Alternative Energy Stocks to Tap AI Data Center Boom from Zacks.com. By Nalak Das. 15. Title: 1 Growth Stock That's Pulled Back 39% and Looks Worth Buying Aggressively Right Now from theglobeandmail.com. By Sneha Nahata at fool.ca. 16. Title: 3 Green Energy Stocks to Buy in July from finance.yahoo.com. By Joel South. 17. Title: 2 AI Infrastructure Stocks That Could Outperform NVIDIA from zacks.com. By Tirthankar Chakraborty. 18. Title: ESG Investors: Why This Dividend ETF Is a Top Pick from ca.finance.yahoo.com. By Baystreet.ca. 19. Title: AI Infrastructure Will Mint More Millionaires Over the Next Decade: 3 Stocks to Buy Right Now from fool.com. By Leo Sun. 20. Title: AI Stocks Investment Strategy 2026: Top Picks & Market Analysis from intellectia.ai. By Jason Huang. 21. Title: 3 Climate Finance Stocks Linked To The World Bank Green Funding Push from simplywall.st. Reviewed by Sasha Jovanovic. 22. Title: BE vs. PLUG: Which Alternative Energy Stock Looks More Attractive? From zacks.com. By Tanuka De 23. Title: 4 High-Growth AI Infrastructure Stocks to Buy for Long-Term Gains from zacks.com. By Anirudha Bhagat. ------------------------------------------------------------- Ending Comment These are my top news stories with their stock and fund tips for this podcast, "July 2026 Sustainable Stock and ETF Picks." Please click the like and subscribe buttons wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And do click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope and prosperity in these tumultuous times! Contact me if you have any questions. Thank you for listening. Again, I want to apologize for my voice sounding, at times, a little rough! My next podcast will be on August 28th. See you then. Bye for now. © 2025 Ron Robins, Investing for the Soul

In this episode of The Lead, host Tina Baykaner, MD, MPH, is joined by Christopher Kowalewski, MD, and Marco Perez, MD, to discuss the journal article, Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study. Together, they review findings from this secondary analysis of the LOOP Study and explore the relationship between genetic risk and atrial fibrillation screening. Learning Objectives Review the key findings from the secondary analysis of the randomized LOOP Study examining atrial fibrillation screening according to genetic risk. Discuss the relationship between genetic risk and atrial fibrillation screening as evaluated in the study. Explore the potential implications of incorporating genetic risk into atrial fibrillation screening strategies.   Host: Tina Baykaner, MD, MPH Guests: Christopher Kowalewski, MD and Marco Perez, MD   Disclosures: T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific   C. Kowalewski No relevant disclosures   M. Perez Ownership/Partnership/Principal: QALY Honoraria/Speaking/Consulting Fee: Boston Scientific, Biotronik Research: Apple, Inc. Other/Stock Options Privately Held

In this episode of the IQVIA MedTech Business Insights Podcast, Michelle Edwards speaks with Arvind Ramadore, Global Head of Innovations for Robotic Surgery Technologies at Medtronic, to discuss how robotics and AI are reshaping the future of surgery. Their conversation explores the opportunities and challenges facing the industry, from evidence generation and reimbursement to regulation, digital ecosystems and the path toward greater surgical autonomy.

What separates companies that consistently grow from those that simply launch products? In this episode, Caitlin Mayer, Senior Director of U.S. Marketing for Medtronic's Acute Care & Monitoring business, shares the go-to-market principles that have helped her team build stronger customer partnerships, align cross-functional teams, and accelerate growth through portfolio-based marketing. Drawing on real-world experience leading commercialization strategies in one of healthcare's fastest-growing care settings, Caitlin explains why today's customers expect more than products. They expect solutions that improve workflows, deliver economic value, and solve meaningful operational challenges. She also shares the planning process her team uses to unite marketing, sales, clinical, and product teams around a single business objective, creating the alignment needed to execute consistently and drive measurable results. What you'll learn: 1. Why portfolio selling creates stronger customer partnerships than product-centric selling. 2. How customer insights should shape positioning, segmentation, and go-to-market strategy. 3. How cross-functional alignment creates better execution and measurable business results. 4. A practical framework for moving from product launches to sustainable revenue growth. About Caitlin Mayer: Caitlin Mayer is the Senior Director of U.S. Marketing for Medtronic's Acute Care & Monitoring business. With more than 15 years of experience in healthcare marketing, she specializes in customer-centered go-to-market strategy, cross-functional alignment, and building commercial programs that drive measurable growth. Resources: • Connect with Caitlin Mayer on LinkedIn • Follow Medtronic on LinkedIn • Explore the Medtronic website

In this episode, we break down four major healthcare cybersecurity incidents: the Craneware billing platform attack, a nonprofit breach affecting 75,000 individuals, Medtronic's exposure of nearly 370,000 patient records, and ApolloMD's $4.02 million settlement following a ransomware attack. These cases underscore critical lessons for healthcare organizations on vendor management, network segmentation, and incident response planning.

Anastasia Mironova is the founder of UpLevelMedTech, a leadership development and executive coaching practice focused on shaping the next generation of medtech executives. Anastasia shares her path from joining Medtronic as an MBA intern to building a career across marketing, strategy, sales, and M&A, and the pivotal moment that cemented her purpose. She breaks down the core themes she sees in leaders at every level—team effectiveness, operating with GM-level ownership, and influence without authority—and explains how “leadership by subtraction” and time inventory create the capacity for strategic impact. She also explores how music shaped her leadership through listening, pausing, and performing under pressure.    Guest links: www.uplevelmedtech.com Charity supported: Save the Children Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 085 - Anastasia Mironova [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of the Leading Difference podcast. I'm your host, Lindsey, and today I'm delighted to welcome as my guest, Anastasia Mironova. Anastasia is the founder of UpLevelMedTech, a leadership development and strategic advisory firm dedicated to shaping the next generation of executives in medtech. Through a blend of executive coaching, strategic advisory, and custom leadership programs, she helps senior leaders and teams elevate their influence, decision-making, and organizational impact. She is a passionate advocate for advancing women in leadership and brings two decades of lived experience navigating corporate growth, career transitions, and motherhood with authenticity and humor. Known for her relatable approach and her ability to make leadership growth feel both practical and empowering, Anastasia helps leaders show up with clarity and confidence in complex environments. When she's not coaching or facilitating programs, she loves spending time with her husband and daughter, often recharging at a beach somewhere and supporting mentoring initiatives that help women lead boldly and thrive in their careers and lives. All right. Well, welcome to the show. Thank you so much for being here today. I'm, I'm really excited to speak with you. [00:01:55] Anastasia Mironova: Thank you for having me. I'm excited also. [00:01:58] Lindsey Dinneen: Awesome. Well, if you wouldn't mind starting off by just sharing a little bit about you, who you are, your background, and what led you to medtech? [00:02:08] Anastasia Mironova: Oh my gosh. My name is Anastasia Mironova, and I'm the CEO and founder of UpLevelMedTech. We are the leadership development and executive coaching practice focused specifically on medtech, but I have not grown up around medtech at all. You probably hear that from other guests, I'm assuming, quite a bit. But I was born and raised in Kazakhstan in Central Asia, and I kind of grew up more around music and entrepreneurship and totally did not know anything about medtech. I came to US in early 2000s to do my MBA program, and one of my classmates was, at the time, working for Medtronic. And when I was finishing my MBA program, she said, "You know, we're hiring for a variety of marketing roles, including an intern, and I was thinking maybe you should apply because you have some of those skills." And I said, "Sure, I, I'm interested." And so the rest is history. I joined as an intern working for Medtronic and eventually worked my way up into product management roles and then global marketing, marketing and strategy, marketing strategy and sales, and then added M&A components to it. So loved it, and I very shortly thereafter, there was a situation that made me completely fall in love with the industry. And I would say that what I really appreciate about it the most is just how much purpose there is behind it, and that's what really connected me to it, and also just how much innovation is being brought forward because I come from a place that didn't necessarily have a lot of innovation readily available, you know, at the speed that we're producing it here. And so I, I really appreciated that, and that's how I-- that, that was my journey in medtech up until I then became a, an entrepreneur and opened up my own business. [00:03:51] Lindsey Dinneen: Awesome. Okay, well thank you for sharing. There's so much I wanna dive into, but you said you did grow up around maybe not medtech, but entrepreneurship and leadership and things like that. Do you mind sharing a little bit about that and what maybe intrigued you? Because obviously you've become not only an incredible leader yourself, but you are coaching other leaders too. [00:04:11] Anastasia Mironova: Yeah, sure. It's, it's a really good question. I grew up around my parents' little, I call it mom-and-pop loving business. That business didn't start until after the wall fell and, and, and all of that, but because the business was so tiny, everybody was involved, and I was very much spending a lot of my time around that. And my mother was my early impact on how I was shaped as a leader later on. Unbeknownst to me, I would say she was what you and I would describe a servant leader today, probably long before that term was coined somewhere in a book or in a business school. But what it really taught me was one thing, which is you're not bound to any specific functional area. You are in the business of something, whatever your business is. And so it taught me to think more broadly and to think like a business person, and I would say, again, I was very unconscious to that at the time. I was just doing a lot of things, helping out, having fun, sometimes thinking about how I absolutely don't know what I'm doing, you know? But then later on, I became more and more self-aware about the fact that how much that business thinking actually helped me to succeed later on as a leader and, and help other leaders grow. [00:05:29] Lindsey Dinneen: Yeah, and I'm curious about that aspect. So you, you said it was lovingly a mom-and-pop place, which is wonderful, and, you know, you said sort of everybody was involved, and I feel, feel like that is a very common theme. And so one of the things that I'd be curious to have your take on is something that I discovered owning my own dance studio is there were, there were a lot of moments that were really fun, right? And you, you got to kinda show up in the community, and you, you had a business, and that's, that's a fun thing to do. But, you know, on any given day, I was everything from the CEO to the janitor, and everything in between. And I think that's a wonderful thing to experience as a leader, but I'm curious as to how that experience probably shaped your own style of leadership beyond being able to observe really good leadership up close and personally. But I'm just kinda curious how that, how, how sort of having a take in all the different aspects of the business may have really helped shape you. [00:06:27] Anastasia Mironova: Yeah. It, it, it's really kind of fundamental when I think about it, 'cause my mom said exactly the same phrase that you just mentioned. She told me always, "You have to be able to get along with everyone equally and treat everyone equally with respect, whether it's a janitor or your CEO, and your ability to get along with every level of the organization is what's going to shape the success." And, and she was very much modeling that behavior. But where I feel it shaped me was that when you work in, in medtech in particular, it's very cross-functional, right? So when you work in a particular area, say I was in marketing in early, in early days, I didn't think of myself as a marketeer. And, and what that meant for me is certainly I would focus on what I needed to do and my goals and our functional area imperatives and all of that, but I always was curious about how does the rest of the business work. And so I didn't think of myself as "I'm a marketing leader." I thought of myself as "I'm a business leader." And when you remain curious in how other aspects of the business work, how it all comes together, what are the macro trends? You know, what do the customers want? How are people compensated? How does the innovation pipeline get shaped? All of those things working together helps early on to make better decisions in your own swim lane. And it kind of like, it shaped me as a leader because I felt that it helped me to make better decisions in larger context in mind. But also it helped me to relate, to relate to a lot of people in a lot of different functional areas, and not assume what their life was like and what their day-to-day was like, but be curious about it. So I would say that definitely both of those things shape how I saw business as well as people in it, if you will. [00:08:18] Lindsey Dinneen: Yeah, I love that. I love the idea of curiosity and being willing to have conversations, meet other people, learn different aspects of the business, 'cause you're absolutely right. The only thing it can do is help you better understand your lane in relation to other people's lanes. And I'm wondering if part of that was also learning how to kind of to, to speak the language of other people's areas of expertise a little bit, in the sense of you're probably going to have a little bit of a different explanation for, say an upcoming project you wanna launch, say, like a, a marketing campaign to the CFO than you would maybe an engineer. So I'm curious how you, how that ha- unraveled for you. [00:08:59] Anastasia Mironova: Oh it was quite a journey. So earlier when, when I first started in medtech, and I was probably on my second role, I had a, a tremendous boss that was very visionary and, and she believed in talent development very much. And she said to me, "You need to go and probably get even more training in influencing and influencing skills." And I was like, "Wow, I would love to do that. I love everything that has to do with human psychology, behavioral, you know, psychology." And so she actually sponsored that, and I was able to do that. And what I quickly found was that the way you position your message and the way you deliver your message and how you influence different people varies drastically. And that really helped me later on as a leader to advocate for my team. I felt like at minimum, the influencing skills and the ability to relate to different people from different walks of life, it helps you to advocate for yourself and for your own initiatives and for whatever you might be focused on. But for leadership, it definitely helped me to be heard as a leader and advocate for my own team later on. And I also felt like other leaders were telling me, "You really understand what it's like to be in our shoes," and therefore were more willing to listen to what I had to say. So it's, it's such a counterintuitive thing at times, but I do believe in this concept of it is our job to inform ourselves of our conversation partner and not the other way around. And it, it works. It's very effective. [00:10:38] Lindsey Dinneen: Yeah, that's, that is, that is incredible and such a great skill set to have and to pass along, and I really love your point about advocating for others as well, in addition to advocating for yourself. And so I know one of the things that you do brilliantly now is to help people who are potentially interested in taking that next step in their own leadership journey, whether they're interested in, you know, going from, let's say, director to VP, VP to C-suite, and things like that. So I was just wondering if you could share a little bit about how you made this successful for yourself, because you mentioned on, on your LinkedIn profile that you didn't work-- It's not like you were working crazy hours, or you were doing all the right things. And so I'd love to hear about your journey and then how you help others too, through their journeys as well. [00:11:27] Anastasia Mironova: Yeah, certainly. I'm thinking about back when most of my career happened, probably while I was very much navigating the demands of everything all at once, the demands of young family or having young family at the time, you know, parents and, and everything that we normally have on our plate. And I firmly believe that as a leader, you have to be very, very clean and clear on what your one or two things are that are super strategic in your world that only you can really do and drive, and this is your primary role. And so one of the ways I did that is I, I definitely was very, very intentional about how I spent my time, and I did a process once a month that had to do with my inventory, time inventory, believe it or not. And I would do it on the plane or, you know, on, on the ride to, to, you know, a, a seminar or something or a meeting, and it really helped me to hone in on these are the things that only I can really ensure to drive, and the rest belongs to my team so that they can shine and they can also, you know, we can be effective together. One of the things that I find the hardest is that people graduate from execution to that strategic impact, and it's hard to do that. Most of the time when I help my clients, the, the challenge is not the capability. It's not the skill set. I work with tremendously talented people. It's the capacity. It's the creation of that leadership capacity, and that takes what I call leadership by subtraction. You have to subtract something to create that space for your strategic impact, and that's what we work on often together, but that's what really truly helped me to be successful, is leadership by subtraction and inventorying it. [00:13:20] Lindsey Dinneen: Yeah. Okay, great. Well, yeah, th- that's great because I'd love to learn more about your company now how you work with people, and kind of where you find perhaps some of the, the hardest things as, as you're growing in your career and your leadership responsibilities increase. So what are, what are some of the common things that you see that don't work well as you're trying to continue to grow in your, in that way? [00:13:46] Anastasia Mironova: For me or for my clients? [00:13:48] Lindsey Dinneen: Let's talk about for your clients. [00:13:51] Anastasia Mironova: Okay. So for my clients, I would say there are definitely very common themes as I see it. It's interesting to me because when I first opened up my business, I had this theory that the kind of challenges that people maybe at an individual level will face might be drastically different from those that are faced at the executive level. And I quickly learned that the challenges are all the same. The way they show up in your day-to-day life may be different, but the challenges are all the same, and they have to do oftentimes with three things. Do you really get laser-focused on how effectively you manage your team so that you and your team can elevate? The second area that's probably by far the most common is, are you operating at that GM level? Even if you're individual contributor, are you thinking from an ownership perspective like an owner would in a business versus a particular title or a particular role in, in honing in on that business, business acumen and the one that crosses all lanes, all company sizes, I would say all teams, all functions is, is influencing skills and presence. How do you show up in a way that honors other people but helps you to move both business and people forward and you have absolutely no authority over them, right? So it's that influence without authority. These are very, very for like front of mind for a majority of the teams that I work with. And I'd say one of the ways to probably, you know, deal with that or address that is, is definitely to be very intentional about development. So it's not just here and there or, you know, as time permits, but as, as the companies become more intentional about the development, the more capacity they create. I definitely believe that our future is not, not in necessarily having high potential development, but high capacity development. [00:15:55] Lindsey Dinneen: Hmm. Yeah. [00:15:56] Anastasia Mironova: If that makes sense. [00:15:57] Lindsey Dinneen: Yeah. So how, how can we encourage companies to prioritize this? 'Cause I, I agree with you that the development all along the path is really important, and I know a lot of people take very personal ownership of that, and they do a lot of their own you know, training and things like that, and coaching. But, but what about from the perspective of a company? How can we encourage companies to be more involved and to understand the importance of the ROI associated with it, just to be frank? [00:16:27] Anastasia Mironova: Yeah. Yeah, for sure. And that's the conversation where I would say the CHROs, the people leaders, are now taking a significantly more active role in companies to allow for that conversation to take place and to have a much deeper partnership with the business leaders to be more intentional about development. And I would say what I see is that's the best practice where they partner together and say, "My needs are like this," right? "These are some of my needs on my team, and here's our solutions. And how do we bring these solutions more systematically to all levels so that we can uplevel everybody?" And companies that do do that and have these conversations, then they, they're more disciplined as well as more prioritized around that topic. And where it doesn't become that partnership conversation on the table, it's harder, certainly harder. And I'm being completely frank and candid on that. [00:17:28] Lindsey Dinneen: Yeah. Yeah, I appreciate that. Yeah. Okay, so one of the things I noticed on LinkedIn is --you have w- several wonderful things. One of them that I really enjoyed was kind of seeing your different book recommendations, so it seems like you are a very avid reader, and also you grew up in a very musical environment, yeah? That's part of your background. So I'd love if you share a little bit about those, and maybe how you think that has helped you as a leader in your career. Just h-how do those things interplay? [00:18:02] Anastasia Mironova: Oh, you, you, you run a risk of getting me into my soapbox a little bit, but mus- yeah, yeah. Music is big. So I, I went to music school for 10 years and learned to, to play piano. But I probably could write a book about the parallels between music and leadership just for fun of it at someday when I retire and have time, because learning music really taught me a lot about leadership in, in a number of ways. If you think about medtech and you think about, again, how much of it is very cross-functional, a lot of different groups have to come together, words like alignment come to mind, right, all the time. In music, it's interesting because you have to listen to yourself as you play to make sure that you self-correct. And so that listening, that ability to listen to "How am I coming off right now?" is, is really important, I think, in leadership, particularly today when everything is more about being more inclusive, right, being more diverse in how you build your team. So I would say that listening ability is huge and shaped me as a leader. And the other one is the power of pause. If you, if you don't pause when you play when you're supposed to, it's just not gonna sound the same. It's not gonna land the same. And so, like that power of pausing to allow for a better response is another huge parallel, particularly in executive levels and like how you show up. And I would say probably the other one is ability to prep. There is a lot of preparation in leadership. You can attest to that. There's a lot of prep that goes into it. But then there comes the time when you have to go and in high stakes be composed and, and read the room and, and, and get there. So lots of parallels. I could think of many more, but these are just like the top three that I would say definitely prepared me, again, when it matters, you know? 'Cause I, I think a lot of times in leadership we talk about, you know, culture and engagement, right? And trust, and those are fundamentally unbelievably important. But I oftentimes think that leadership falls apart in those high-pressure moments, right? And music prepared me to deal with that quite a bit, so. [00:20:23] Lindsey Dinneen: Yeah. Oh, I love that. So I t- I talk about this quite a bit too with s- my background is also in the arts, but on the dance side. I'm a professional ballerina, and, and one of the things that I often talk about is how, yeah, it prepares you for really high-stakes environments where you're gonna go in, and honestly, it doesn't really matter what kind of day you've had, what you, what's going on in your life. You're there to perform, so you have to learn to show up poised and in command and with confidence that may or may not actually exist. [00:20:56] Anastasia Mironova: Yes, definitely. Definitely. Yeah. Yeah, you have to compartmentalize it all. And even if you make a mistake, which is inevitably that does happen on stage when people are watching and all eyes are on you, and there, lo and behold, you tripped on a note or it didn't land quite there, and you just have to keep going. And I think that that skill is tremendous in leadership. [00:21:25] Lindsey Dinneen: Yeah, could not agree more. Okay, so you mentioned when you were first telling us a little bit about your story that there was a moment that kind of really made you fall in love with the industry or, or helped you feel fairly passionate about it, and I was just wondering, I always love learning what, what is a moment or a couple of moments that stand out to you as just affirming, "Wow, I am in the right place at the right time"? [00:21:50] Anastasia Mironova: Yeah, it's, it's a little bit of an emotional story, but I started my career in medtech in a external defibrillation category, which in simple terms, at the time, it wasn't something that was mandatory in schools, stadiums, airports, planes, you know, all these things were now are equipped with a little portable defibrillator wasn't the case. The laws haven't yet been passed, and so we were pretty early days, and we had to fight oftentimes very hard to get one of these into, say, schools. And so one of our team mem- members on the sales side did that, and later on, I met a six-year-old boy with his mom who survived sudden cardiac arrest in the school that we were able to fight and place the AED in because he collapsed with sudden cardiac arrest. And so we, we brought him to, to our company, and this little human was on stage, you know, alive because so many people carried that part, right? And I just get emotional just talking about it. That was my moment. It was really early on, and I literally just committed to it and never looked back. And I'm so happy that he was there , and then we met many more, you know, throughout the years, but that was my pivotal moment for sure. [00:23:10] Lindsey Dinneen: Oh, that's such a beautiful story. Thank you for sharing that. I, yeah, that, yeah. I can see why that would get you every time because what an amazing, what an amazing thing to get to... 'Cause, you know, you, you know you're in a good industry doing good things, but when you get to see the impact on a patient, and a little human and to top it all off, oh my gosh, that's, that's beautiful. Yeah. [00:23:34] Anastasia Mironova: Thank you. Kids, right? And, and, and I've met a few patients since then that have been positively impacted, adults, various ages. And again, it just-- it's such a reminder every time. Even when I now work with my clients and I, you know, would talk to them about whatever their challenges are and work through that, most all of them share that and tell me, " Yesterday I was reminded, you know, because I met-- I went to the hospital, and I met, you know, some, some patients." It's unbelievable. Purpose. [00:24:05] Lindsey Dinneen: Yeah, exactly. Yeah. Yeah, yeah, absolutely. Well, okay, pivoting the conversation a little bit just for fun, and based on a previous answer, now I'm, I'm wondering if this will be similar, but imagine that you were to be offered a million dollars to teach a master class on anything you want. Could be within your industry, it doesn't have to be. What would you choose to teach? [00:24:28] Anastasia Mironova: I would choose, I would choose to teach two things. One would be how to not fall apart under pressure, for sure. I would teach that in a heartbeat because I feel like there's just so much to it, and it's fun. It's actually fun. It's very, very learnable, and contrary to people's belief, anybody can learn that. So I would totally teach that. And I would teach it, believe it or not, how to tailor your message. The marketeer in me is still very much alive. I would teach about you can take this one thing that you really need to deliver and deliver it 16 different ways, and this is the one or two ways that it's going to get it landed, whether it's your investor pitch, your initiatives, your budget, your people, whatever you need. There's so much power in that, in tailoring it to the audience, and I have fun doing that, so I would probably teach those two things. [00:25:27] Lindsey Dinneen: I love that. That's awesome. Okay, and then how do you wish to be remembered after you leave this world? [00:25:33] Anastasia Mironova: That's a weighty question. Probably in two ways. For me, my most important values are my family, if you haven't guessed that already. So I would want to be remembered that I've spent a lot of really good special moments with my daughter and with my family because I feel like that's, that's what matters at the end of the day. And I would like for all the people whose lives I touch today and throughout my career leave with feeling more clarity, lighter, and just more uplifted after talking to me, and so that I leave them better off than when we started because that's, that's the legacy I want to create. I do believe both leadership as well as our personal life are comprised of those hundreds of very small moments, and that's how I would like to be remembered probably. [00:26:26] Lindsey Dinneen: Yes, I, I love that. I-- that's a beautiful legacy, yeah. All right, and then final question: What is one thing that makes you smile every time you see or think about it? [00:26:40] Anastasia Mironova: My daughter's paintings, hands down. So I have a, an artist in the house, which I, I'm not artistically inclined from, from, from a painting perspective. Music, right, not painting. And she paints a lot, and so every time I see something being created, whether it's silly or serious, whatever she- her, her mood is at, it just makes me smile. So it's my, it's my instant instant smile of the day. [00:27:04] Lindsey Dinneen: Oh, I love that. Yes, I, I love art in general, and very much share the same, you know, idea that there's so much that you can take from what you learn from the discipline of, of being in the arts to where you go in the future. But anyway, that's so much fun to hear, so thank you for sharing. And just in general, thank you so much for being here today. I really appreciate it. We are so honored to be making a donation on your behalf as a thank you for your time today to Save the Children, which works to end the cycle of poverty by ensuring communities have the resources to provide children with a healthy, educational, and safe environment. So thank you so much for choosing that charity to support. I, I loved hearing your stories and your advice, and I appreciate how you're helping the next generation of leaders to succeed. This is such an important industry, and we want people to be successful, so thank you for the work you're doing to change lives for a better world. [00:28:05] Anastasia Mironova: Oh, thank you, Linds. Thank you for having me. I am really honored. You bring such wonderful guests always, that I look forward to your next episodes as well. Thank you very much for having me. I had so much fun talking to you. [00:28:16] Lindsey Dinneen: Awesome. Good. Well, thank you, and until next time. [00:28:20] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.

Recorded at EHRA 2026, this episode of The Lead features host Christopher Kowalewski, MD, in conversation with Christian Sohns, MD, and Pierre Jaïs, MD, about the journal article, 20 Years: Clinical Outcome After Pulmonary Vein Isolation in Patients With Symptomatic Drug-Refractory Paroxysmal Atrial Fibrillation. Together, they discuss the study's long-term clinical outcomes following pulmonary vein isolation in patients with symptomatic drug-refractory paroxysmal atrial fibrillation and explore the implications of two decades of follow-up.   Learning Objectives: Review the long-term clinical outcomes reported after pulmonary vein isolation in patients with symptomatic drug-refractory paroxysmal atrial fibrillation. Discuss the implications of 20-year follow-up data for the treatment of patients undergoing pulmonary vein isolation. Examine how long-term outcome data may inform clinical decision-making for catheter ablation in paroxysmal atrial fibrillation.   Host: Christopher Kowalewski, MD   Guests: Christian Sohns, MD and Pierre Jaïs, MD   Disclosures: C. Kowalewski No relevant disclosures   C. Sohns No relevant disclosures   P. Jaïs Ownership/Partnership/Prinicipal: inHEART Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., Boston Scientific, Medtronic

Host: Rasha Al-Lamee Guests: Christina Magnussen Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2559   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartis, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Risk factors and longevity in women and in men  Mythbusters: Smartphone interference with pacemakers, ICDs Host: Rasha Al-Lamee Guests: JP Carpenter, Christina Magnussen Want to watch that episode? Go to: https://esc365.escardio.org/event/2559 Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartiq, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this episode of Medsider Radio, we sat down with Bob Paulson, President and CEO of Sonex Health. Sonex's UltraGuideCTR device is a minimally invasive technology that enables ultrasound-guided carpal tunnel release procedures to be performed outside the surgical suite using local anesthesia, expanding patient access and reducing the cost of care.Before joining Sonex, Bob led multiple venture-backed medical device companies through commercialization, including NxThera, acquired by Boston Scientific, Restore Medical, acquired by Medtronic, and VentureMed Group. Earlier in his career, he held senior leadership roles at Medtronic, Advanced Bionics, and Endocardial Solutions, which was acquired by St. Jude Medical.In this interview, Bob explains how to build a reimbursement strategy before your first clinical study, drive physician adoption when introducing a new care pathway, and raise capital aligned with value inflection points. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Bob Paulson, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:19) - Bob's path from Medtronic to multiple medtech exits before joining Sonex (05:38) - Why 80% of eligible carpal tunnel patients avoid surgery — and how Sonex is changing that (11:11) - The reimbursement challenge that reshaped Sonex's clinical evidence strategy (19:07) - Reimbursement is a three-leg process: FDA, CPT, and payer coverage (22:07) - Reverse engineering your company from the exit you're trying to achieve (29:35) - How Sonex helped surgeons move carpal tunnel procedures out of the OR (39:06) - Sonex's "pitcher-catcher" approach to physician and patient adoption (41:59) - Bob's framework for choosing investors who can finance the entire journey, not just the next round

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show

Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Kenneth Ellenbogen, MD, FHRS, about the journal article, Real-time smartphone alerts during atrial fibrillation episodes with implantable cardiac monitors and wearable devices: SMART-ALERT study. Together, they discuss the study findings and explore the use of real-time smartphone alerts in conjunction with implantable cardiac monitors and wearable devices during atrial fibrillation episodes. Learning Objectives Review the design and key findings of the SMART-ALERT study evaluating real-time smartphone alerts during atrial fibrillation episodes. Discuss the use of implantable cardiac monitors and wearable devices for real-time detection and notification of atrial fibrillation episodes. Explore the potential clinical implications of integrating smartphone alerts with cardiac monitoring technologies.   Host: Michael S. Lloyd, MD, FHRS   Guests: Tina Baykaner, MD, MPH Kenneth A. Ellenbogen, MD, FHRS   Disclosures: M. Lloyd ·      Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other   T. Baykaner ·      Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific ·      Research: NIH, Boston Scientific   K. Ellenbogen ·      Honoraria/Speaking/Consulting Fee: American College of Cardiology, Heart Rhythm Society, Boston Scientific, Medtronic, Inc., Abbott ·      Royalty Income: Wiley-Blackwell, Elsevier

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the latest advancements shaping the future of drug discovery and patient care. Veradermics is making significant strides with its oral minoxidil formulation aimed at addressing female pattern hair loss. The mid-stage clinical trial results have analysts optimistic about Veradermics' potential to capture a significant portion of this underserved market. The oral form of minoxidil, traditionally used in topical Rogaine products, offers a novel delivery method that could enhance patient adherence and improve outcomes, marking an innovative leap in dermatological treatments. Johnson & Johnson is navigating the expiration of Stelara's patent protection with resilience, as Tremfya steps up to fill the revenue gap. With quarterly sales exceeding $2 billion, Tremfya underscores the critical role of strategic lifecycle management and robust product pipelines in weathering patent cliffs. This success highlights the necessity for pharmaceutical companies to sustain growth through a well-rounded portfolio that can absorb such impacts. In oncology, Celcuity has achieved a pivotal milestone with FDA approval for its small molecule inhibitor targeting breast cancer. This therapy promises blockbuster potential and could become a new standard-of-care, expanding treatment options for patients. The approval reflects ongoing innovation in oncology, where small molecules continue to play an essential role alongside biologics in advancing cancer therapies. AI-driven drug discovery is gaining traction as Insilico Medicine partners with CDMO Bora in a potentially $2.5 billion deal. This collaboration underscores AI's transformative potential in accelerating drug discovery and development processes. By leveraging artificial intelligence, Insilico aims to identify new drug candidates more efficiently, expediting their journey from bench to bedside. Kelun-Biotech is marking significant progress with its SAC-TMT program targeting non-small cell lung cancer (NSCLC), filling gaps left by Merck's phase 3 efforts. This development is crucial for providing more tailored therapeutic options in oncology, illustrating how advancements in drug development are driving forward personalized medicine. Roche continues its exploration of Alzheimer's disease treatments with a multifaceted approach that includes both amyloid and tau proteins as targets. While its phase 3 amyloid program is prominent, Roche's interest in tau protein highlights the complexity of tackling neurological disorders and the need for diverse therapeutic strategies. Meanwhile, Biogen remains steadfast in defending its anti-tau Alzheimer's candidate following mixed phase 2 results that showed slowed cognitive decline. Despite stock volatility, this endeavor illustrates the high-stakes nature of Alzheimer's research as companies pursue novel approaches to this challenging disease. Regulatory landscapes are also shifting as Johnson & Johnson halts development of an eye disease gene therapy after disappointing phase 2b results. This move reflects the inherent risks involved in gene therapy and underscores the necessity for thorough evaluation at each clinical stage. Medtronic's recall of its Harmony delivery catheter system due to potential detachment risks serves as a reminder of the paramount importance of safety and quality control in medical device manufacturing. Such recalls impact patient safety and emphasize regulatory vigilance over device reliability. In summary, these innovations demonstrate the dynamic nature of the pharma and biotech industries where cutting-edge science drives progress. Integrating AI into drug discovery, managing product lifecycles post-patent expiry, advancing personalized medicine, and maintaining regulatory diligence collectively shape a landscape focused on improving patient outcomes worldwide. Turning to recent scientific developments: Eli Lilly's presentation at AAIC 2026 on their anti-amyloid Alzheimer's drug Kisunla explores maintenance therapy possibilities once amyloid levels fall below a threshold. This potential shift could signify a paradigm change by extending therapeutic benefits and possibly improving long-term outcomes for patients with Alzheimer's. Biogen's advances with its anti-tau Alzheimer's therapy partnered with Ionis Pharmaceuticals further validate the tau hypothesis. The promising mid-stage data on their antisense drug Diranersen opens opportunities for other companies like Denali Therapeutics to explore similar avenues for treating neurodegenerative diseases. The industry is also witnessing a resurgence in biotech IPOs during 2026's first half, recovering from a sluggish 2025. This surge signals investor confidence in biotechnological innovation while providing capital for advancing research pipelines. Financial activities within the sector are robust as Attovia Therapeutics files for an IPO to fund its competitive pipeline against Sanofi's Dupixent. Meanwhile, Advancell's $315 million Series D funding supports advancing prostate cancer candidates into Phase 3 trials, backed by big pharma confidence in radiotherapy's potential. Lastly, regulatory transparency improves as the FDA resumes releasing drug rejection letters after a temporary pause—a move likely to influence future submissions significantly by offering clearer guidance on regulatory expectations. These developments collectively highlight how scientific innovation and strategic maneuvers transform pharmaceutical landscapes, promising profound impacts on patient care through advanced therapies and novel treatments worldwide. As these trends unfold, they reflect an industry increasingly reliant on technological integration and collaborations to drive future growth and innovation.Support the show

Ministre, femme politique, chroniqueuse, auteure, femme de culture et de convictions, Roselyne Bachelot a occupé des fonctions parmi les plus exposées de notre pays, sans jamais renoncer à sa liberté de ton, à son humour, ni à sa capacité à bousculer les cadres établis.Mais derrière la femme publique se trouve aussi une histoire faite d'héritages familiaux, de transmission qui ont forgé des convictions et des combats résolument féministes.La transmission, qui était la thématique de cette 5ème édition des Legend Ladies Nights, c'est aussi transformer une histoire personnelle en parole publique, et une parole publique en possibilité de changement.Dans son dernier livre "Une omerta française", secrets d'enfance, Roselyne Bachelot choisit de mettre des mots sur ce qui a longtemps été tu. Elle interroge les mécanismes du silence, la manière dont les familles et les institutions protègent parfois davantage leur équilibre apparent que les enfants eux-mêmes, mais aussi notre responsabilité collective à regarder, écouter et agir.Car transmettre, c'est aussi avoir le courage de rompre certaines chaînes.C'est refuser que les blessures, les violences ou les silences passent d'une génération à l'autre.Une conversation sur l'enfance, l'engagement, le courage, la liberté et la trace que nous choisissons de laisser.Cette cinquième édition des Legend Ladies Nights a été rendue possible grâce au soutien précieux de nos partenaires : Medtronic, Mastercard, Release Capital et Mediawan.

Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Prashanthan Sanders, MBBS, PhD, FHRS, about the journal article, Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid Cardiomyopathy and Sinus Rhythm. Together, they discuss the study findings and explore the relationship between atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy who are in sinus rhythm.   Learning Objectives: Review the key findings of the study examining atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy and sinus rhythm. Discuss the association between atrial mechanical contraction and cerebrovascular risk in this patient population. Explore the potential clinical implications of assessing atrial mechanical function in patients with transthyretin amyloid cardiomyopathy.   Host: Michael S. Lloyd, MD, FHRS   Guests: Tina Baykaner, MD, MPH Prashanthan Sanders, MBBS, PhD, FHRS   Disclosures: M. Lloyd Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other   T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific   P. Sanders Honoraria/Speaking/Consulting Fee: Boston Scientific, Abbott Medical Other Financial Relationships: Medtronic PLC, Pacemate, CathRx Research: Abbott, Becton Dickinson, Calyan Technologies, Ceryx Medical, Biosense Webster, CathRx, HelloAlfred, Medtronic, Inc., Abbott Medical

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

July 8, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Gallup survey finds 11% of US adults now take GLP-1s for weight loss, nearly quadruple 2024, as compounded versions gain share on cost American Time Use Survey shows only 30% of adults socialize daily as gyms and studios grow 60% over 15 years, filling the social gap Medtronic partners with Corsano Health to bring FDA-cleared multi-parameter wearable to hospitals, moving continuous monitoring into clinical care Today's episode is brought to you by AIIR — a modern communications and experiential agency for health, wellness, fitness, and performance brands. From earned media to events and creator-led campaigns, AIIR helps companies sharpen their story, earn attention, and build trust that compounds. Visit https://aiir.agency to learn more. More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe  Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider  Reach out → insider@fitt.co 

Your Social Security number and health history could be sitting on a criminal's hard drive right now, and you wouldn't find out until the letter shows up in your mailbox. That's exactly what happened to nine million Medtronic customers. This week, a global medical giant, a city right outside Atlanta, and an attack run start to finish by artificial intelligence all point to the same uncomfortable lesson. *Nobody is too small to hack, and the basics still decide who survives.* Bryan Hornung, Randy Bryan, and Reginald Andre break down this week's stories for executives, owners, and operators who don't have time to keep up with cyber news but can't afford to be blindsided by it either. First up, Medtronic. The company that makes pacemakers and insulin pumps is now notifying about nine million people that their names, birth dates, Social Security numbers, and health information were stolen by a crew called ShinyHunters. Here's the part that should worry every business owner: ShinyHunters didn't need a genius hack to get in. They called an employee, pretended to be tech support, and talked their way past the front door, the same move that works on your team. Even a company this size is looking at a cleanup that averages 279 days for a healthcare breach, and a small business doesn't have that kind of runway. Then we bring it home. On June 8th, the City of Acworth, right here in Cobb County, got hit hard enough to call in outside cybersecurity pros and law enforcement. Weeks later, the city still won't say what kind of attack it was or whether any data walked out the door. The good news buried in the story: everything was restored with no lasting disruption, which almost always means one thing, working backups. Government ransomware jumped about 65 percent in the first half of 2025, and attackers hunt small cities for the same reason they hunt small businesses: thin teams and tight budgets. We close with the one that keeps us up at night. Researchers at Sysdig say they caught the first ransomware attack run entirely by an AI, no human at the keyboard. It broke in, stole credentials, locked up a database, and wrote its own ransom note. When one login failed, it diagnosed the problem, rewrote its own code, and was back in within about 31 seconds. And in this case, even paying the ransom may not have brought the data back, which means backups are not your plan B anymore, they are your plan A. Three very different targets. One playbook that decides who walks away fine and who doesn't. In this episode, we discuss: • The Medtronic breach that exposed Social Security numbers and health data for about nine million people • Why a cyberattack on the City of Acworth is a preview of what hits small businesses • The first ransomware attack researchers say was run entirely by an AI, with no human directing it • Why the size of the target stopped mattering a long time ago • The three boring fundamentals, backups, multi-factor, and patching, that decide how every one of these stories ends • What business owners should actually check this week before they need it Security Squawk is a weekly podcast and live stream for business owners and executives. Support the show: buymeacoffee.com/securitysquawk Subscribe | Like | Share #SecuritySquawk #CyberSecurity #Medtronic #ShinyHunters #DataBreach #Ransomware #AI #Acworth #SmallBusiness #VendorRisk #MSP #BusinessRisk

This episode of BHIS - Talkin' Bout [infosec] News covers the latest cybersecurity headlines, including debate over the economics of AI infrastructure, updates on the Huntress controversy, new details surrounding Scattered Spider, a critical Microsoft SharePoint vulnerability, and reports of a breach involving a DHS information-sharing network. The discussion also examines Apple's legal battles over alternative app stores, the limitations of Apple's Hide My Email feature, a Medtronic breach, firmware security, Palo Alto Networks attribution disputes, and other notable security stories that didn't make the main rundown.Join us LIVE on Mondays, 4:30pm EST.A weekly Podcast with BHIS and Friends. We discuss notable Infosec, and infosec-adjacent news stories gathered by our community news team.https://www.youtube.com/@BlackHillsInformationSecurityChat with us on Discord! - https://discord.gg/bhis

Join Our Medical Device Sales Program: https://click.newtomedicaldevicesales.com/yt-503

Join Our Medical Device Sales Program: https://click.newtomedicaldevicesales.com/yt-503

Diabetes technology is evolving faster than most people realize — and Ken and Graham break down exactly what that means for your day-to-day management. Plus, Ken closes with something every person living with diabetes needs to hear right now.

In this episode of The Lead, host Robert Schaller, DO, FHRS, is joined by Tina Baykaner, MD, MPH, and Maulin Shah, MD, to discuss the journal article, Device-Related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-Term Follow-Up: The PRAETORIAN-XL Trial. Together, they review the study's long-term follow-up findings and explore device-related complications associated with transvenous and subcutaneous defibrillator therapy.   Learning Objectives: Review the long-term follow-up results of the PRAETORIAN-XL Trial comparing transvenous and subcutaneous defibrillator therapy. Discuss device-related complications associated with transvenous and subcutaneous implantable defibrillator systems. Examine the clinical considerations of defibrillator therapy selection based on long-term device-related outcomes.   Host: Robert Schaller, DO, FHRS  Guests: Tina Baykaner, MD, MPH and Maulin Shah, MD   Disclosures:   R. Schaller Honoraria/Speaking/Consulting Fee: Philips, Abbott Medical Officer/Trustee/Director/Committee Chair/Other Fiduciary Role: Imricor Other Financial Relationship: Other   T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific   M Shah No relevant disclosures

Shortly after BW Chairman Bob Chapman passing in March 2026, it was announced that Pat Berges had been named CEO and Managing Partner of Chapman & Co. Leadership Institute. Chapman & Co. was founded by Bob to bring Truly Human Leadership to organizations around the world, improving their leadership, culture and performance.  Pat was a longtime friend and colleague of Bob's, bringing more than 25 years of global leadership experience to Chapman & Co. He shares the convictions that drove Bob's legacy. Pat is the founder of H3 Leadership, now part of Chapman & Co., and has held senior leadership roles at Covidien and Medtronic. He previously served as executive director of The Curve Initiative, a nonprofit founded by bestselling author Simon Sinek, and has led large-scale leadership development and culture transformation efforts across more than 100 countries. On this episode of the Truly Human Leadership Podcast, Pat talks about his friendship with Bob and how his mentorship was inspiring and challenging. Pat talks about his leadership journey, the future of Chapman & Co. and why their work is more important now than ever.  

It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more  I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: https://diabetes-connections.com/events/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript & links:    Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. https://medicalxpress.com/news/2026-06-beta-cells-players-diabetes.html XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/   XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy.   In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings.     Following is a transcript of his remarks:   What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses.   Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity].   And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%.     However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment.   Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment.   Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure.   And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin.   So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment.   So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it's not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: "The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients." https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance.  Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They've added that to include people diagnosed with type 1 who've been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. https://www.bbc.com/news/articles/ce8mzd94r76oXX XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care.  Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing.   The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. https://www.drugdeliverybusiness.com/dexcom-launches-enhanced-stelo-app/ XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season.   https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/

Episode summary: In this episode of Insights Unlocked, Nathan Isaacs sits down with Robyn Bolton, founder of Mile Zero and author of Unlocking Innovation: A Leader's Guide to Turning Bold Ideas into Tangible Results, to explore why innovation fails so often inside successful companies—and what leaders can do about it. Drawing on her experience at P&G, BCG, and Innosight (Clayton Christensen's firm), Robyn shares the frameworks, mindset shifts, and leadership behaviors that separate real innovation from the illusion of it. Robyn makes the case that innovation isn't an idea problem—it's a leadership problem. She dives into how to set the right conditions before any brainstorming begins, why "innovation theater" breeds cynicism rather than creativity, and how customer insights are the most underutilized asset in most organizations. She also weighs in on AI: what separates the companies genuinely benefiting from it versus those just chasing the next shiny object. You'll learn: Why innovation is a leadership problem, not an idea problem How to define a "growth gap" before you ever go to the whiteboard What "innovation theater" looks like and why it backfires Why customer insights are everyone's job—not just the research team's How to build a culture of innovation (and why it takes years, not events) What separates companies getting real value from AI from those just experimenting A practical "George Costanza" leadership habit you can try this week Innovation starts with leadership, not ideas Robyn Bolton has spent her career helping large, successful companies do something that doesn't come naturally to them: innovate. From launching Swiffer at P&G to working with companies like Medtronic, Nike, and Sanofi, she's seen firsthand what makes innovation work—and what kills it. Her core argument is simple but counterintuitive: innovation doesn't fail because companies run out of ideas. It fails because leaders don't create the conditions for those ideas to survive. Culture, she says, is "the perception of what matters, as evidenced by the actions of executives." If you want a culture of innovation, you have to invest in it consistently for years—not just run an annual hackathon and hope for the best. Customer insights are everyone's job Few topics generate more conviction from Robyn than customer insights. She believes deeply that understanding customers—not just gathering data about them—is a responsibility that belongs to everyone in an organization, including executives. Her prescription is simple: get out of the office, be present with customers in their actual environment, and have the humility to listen rather than explain. Too many "insight sessions" turn into selling sessions, she notes. Real discovery means asking open-ended questions and resisting the urge to justify why the product works the way it does. She shared a vivid example: while working with a medical device company, she and the president of the business unit watched video footage of patients using their products. Within ten minutes, R&D team members were shouting at the screen—convinced the patients were doing it wrong. "They're not wrong," Robyn said. "They're teaching us." Resources & links Robyn's website, Mile Zero (https://www.milezero.io/) Robyn's book, Unlocking Innovation (https://www.amazon.com/Unlocking-Innovation-Leaders-Turning-Tangible/dp/1774585618) Robyn's personal website (https://robynmbolton.com/) Robyn on LinkedIn (https://www.linkedin.com/in/robynmbolton/) Nathan Isaacs on LinkedIn (https://www.linkedin.com/in/nathanisaacs/) Learn more about Insights Unlocked: https://www.usertesting.com/podcast

What if autoimmune disease could be treated without another injection, infusion, or daily pill? In this episode of Entrepreneur Rx, host John Shufeldt sits down with Nishant Doctor, founder and CEO of Surf Therapeutics, to discuss his journey from medtech engineer to healthcare entrepreneur. Nishant shares how nearly two decades in neuromodulation, R&D, clinical development, and commercialization led him to build Surf Therapeutics, a Stanford spin-out developing a breakthrough ultrasound neuromodulation platform for autoimmune disease. The conversation explores the science behind Surf's at-home, non-invasive ultrasound therapy device for rheumatoid arthritis, the role of the spleen and inflammatory pathways, what it takes to build and test medical technology in a startup environment, and why speed, data, accountability, and solution-oriented thinking matter so much in early-stage innovation. John and Nishant also discuss leadership, technical founders, the future of AI, and what it means to build something that may feel non-consensus today but could change how patients are treated tomorrow.  About Nishant Doctor: Nishant Doctor is the founder and CEO of Surf Therapeutics. He has more than 18 years of experience leading R&D and commercial efforts at medtech and neurotechnology companies, including Medtronic, Abbott, and LivaNova. Trained as an engineer, Nishant has helped build multiple implantable Class III medical devices and has also been closely involved in the sales and commercialization of those technologies. His career has focused on neuromodulation, medical device innovation, and translating complex science into technologies that can improve patient care.  About Surf Therapeutics: Surf Therapeutics, a Stanford spin-out, is building a breakthrough ultrasound neuromodulation platform to treat autoimmune disorders, like Rheumatoid Arthritis (RA) —conditions that leave over 2 million Americans without effective or tolerable treatment options, even with blockbuster drugs like Humira and Rinvoq. After years of foundational research at Stanford, they've developed the first of its kind, at-home non-invasive ultrasound therapy device that is used just for a few minutes a day and validated to be clinically safe and effective for treatment of RA.    About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm that invests in innovative companies across healthcare, technology, defense, and other emerging industries. Through multiple funds and investment vehicles, including the Jetstream Venture Fund, the firm partners with visionary founders, provides strategic guidance, and helps connect investors with opportunities in the private markets. Its portfolio includes companies developing solutions that have the potential to transform industries and improve lives.  About Jetstream Venture Fund: Jetstream Venture Fund is an interval fund managed by Xcellerant Ventures and Sweater Industries LLC, that seeks to provide investors access to early-stage, high-growth companies with flexible terms, lower minimums (⁠$5,000 minimum investment⁠), and no carried interest. Jetstream is one of the first funds of its kind, bringing venture-style investing opportunities to a wider professional audience. Back-end administration is provided by Sweater Ventures a ground-breaking turnkey fund management company.  Note: The Jetstream Venture Fund has invested in Surf Therapeutics.  Disclosure for Jetstream: Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The prospectus contains this and other information about the Fund and can be obtained by emailing ⁠⁠jetstream@sweaterfunds.com⁠⁠ or by visiting the ⁠⁠Fund's website⁠⁠. Please read the prospectus carefully before investing. 

A conversation with Brett Wall Find the video of this conversation at https://youtu.be/uxAWCtrDSnQ

It's In The News - a look at the top diabetes stories and headlines happening now!   Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: fall Detroit and Seattle.   Okay.. our top story this week: XX The FDA approved Tzield for use in stage 3 T1D – that's what we used to just call type 1. It's the stage where the body can no longer produce enough insulin on its own to manage blood sugars you need to start insulin. This approval is for kids ages 8-17 within 8 weeks of a stage 3 T1D diagnosis. It comes after the PROTECT trial and it's the first approval of a disease-modifying therapy for stage 3 T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-celebrates-approval-of-tzield-for-use-in-stage-3-type-1-diabetes-in-the-us-302799532.html XX Encouraging results from a small study of islet cell transplantation in people with type 1 where now all 12 participants in the trial are currently living without external insulin after receiving transplanted insulin-producing islet cells.   The study, led by researchers at the University of Chicago, tested an experimental immune therapy called tegoprubart Te-GO-Proo-Bart. The drug is designed to prevent the body from rejecting transplanted cells while avoiding some of the side effects associated with standard anti-rejection medications. You've probably heard about this as the Eledon study – many of the participants have been very active on social media. It was presented at ADA. transplants.https://www.breakthrought1d.org/news-and-updates/tegoprubart-islet-transplant-all-participants-off-external-insulin/ XX New data suggest that acmopatide (ack-MOW-puh-tyd) (CT-868), an experimental once-daily dual GLP-1/GIP receptor agonist, may help people with type 1 diabetes improve blood sugar control, lose weight, and reduce insulin use. Across all doses, participants lost up to 7% of their body weight and reduced insulin use by as much as 15%. The study lasted just 16 weeks, so researchers say longer-term data will be needed to determine whether the benefits can be maintained and whether lower insulin requirements can be achieved without increasing the risk of hypoglycemia. XX A new combination therapy that pairs an amylin analog with semaglutide improved both blood sugar levels and weight loss in several groups of people with type 2 diabetes. The once-weekly injectable, known as CagriSema (KAG-ruh-SEM-uh), was evaluated in three Phase 3 REIMAGINE studies. In people early in the course of type 2 diabetes, researchers reported A1C reductions of up to 1.8 percentage points and significant weight loss compared to placebo after 40 weeks of treatment. Investigators also noted improvements in several cardiometabolic risk factors, including blood pressure. https://www.medpagetoday.com/meetingcoverage/ada/121658 XX Stelo for kids is now FDA cleared.. the over the counter Glucose Biosensor System is now approved for children as young as 2 years old who do not use insulin. The FDA identified pediatric prediabetes as a growing public health concern motivating the expanded indication, noting OTC CGMs can help younger users and their caregivers build glycemic awareness, track patterns in response to me https://www.hcplive.com/view/fda-clears-first-otc-glucose-monitor-for-children XX Insulet presented new data from its STRIVE and EVOLUTION 3 studies showing improved glucose control with its next-generation Omnipod 6. That's , the company's upcoming hybrid closed-loop system for people with type 1 and type 2 diabetes. The main difference between the Omnipod 6 and Insulet's current Omnipod 5 patch pumps is that the new system has a lower glucose target of 100 mg/dL and better Bluetooth connectivity Insulet also shared progress on a fully closed-loop system designed specifically for type 2 diabetes. It  does not require carb-counting or insulin bolusing ahead of meals. Physicians also don't need to program the starting settings.   XX Abbott shared new research highlighting challenges in identifying and managing diabetic ketoacidosis (DKA). The studies coincide with the company's development of Libre Duo, a dual glucose-ketone sensor that continuously tracks both measurements. Abbott reported that DKA can be difficult to recognize when patients first arrive at the hospital, based on data from more than 100,000 people. The company has submitted the dual sensor to the FDA and recently received CE Mark approval in Europe. More news from ADA including info from Dexcom, Sequel, Sensonics and the world loses a tireless T1D advocate.. that's all to come right after this. --   Back to the news.. XX   Dexcom announced its acquisition of Nutrisense, a company that combines continuous glucose monitoring with nutrition coaching and behavioral support. At ADA, the company also presented results from the CONNECT study showing significant A1C reductions and improved glucose control in people with type 2 diabetes not using insulin. The findings add to growing evidence supporting CGM use beyond intensive insulin therapy. We did an episode with CEO Jake Leach at ADA about these announcements as well as updates on G8, their hospital product and much more. XX Sequel Med Tech reported positive clinical results evaluating its twiist automated insulin delivery system in people with type 2 diabetes. The study showed improvements in A1C and time in range over 13 weeks XX Senseonics presented new real-world data supporting the performance of its Eversense 365 implantable CGM. The analysis included more than 12,000 sensors and demonstrated sustained accuracy and effectiveness in both open-loop and automated insulin delivery settings. Researchers also evaluated Eversense use with Sequel Med Tech's twiist system. The findings support broader use of long-term implantable CGM technology.   -- MiniMed used ADA 2026 to spotlight two recently cleared diabetes management systems. The MiniMed Flex pump offers a smaller, smartphone-controlled insulin pump option, while MiniMed Go combines the InPen smart insulin pen with Abbott's Instinct sensor. The products received FDA clearance earlier this year. XX Tandem Diabetes Care highlighted data supporting the use of its Control-IQ automated insulin delivery technology during pregnancy. Results from the CIRCUIT trial showed users spent approximately three additional hours per day in the recommended pregnancy glucose range compared with standard therapy. The findings helped support recent regulatory approvals for pregnancy use in both Europe and the United States. Tandem also expanded indications for adults with type 2 diabetes. XX Beta Bionics presented real-world data from the first three years of iLet Bionic Pancreas use. The company reported a 25% improvement in time in range among users, along with positive feedback from clinicians about simplified diabetes management. The iLet system requires only a user's weight to begin therapy and eliminates carbohydrate counting. Beta Bionics also highlighted growing access to near-real-time outcomes through its public data dashboard. XX MannKind presented new findings supporting its Afrezza inhaled insulin at ADA 2026. A post-hoc analysis of the INHALE-1 study found that pediatric users reported greater treatment satisfaction compared with those using rapid-acting injected insulin. The results come shortly after FDA approval expanded Afrezza's indication to include children. We did a bonus episode with one of the lead investigators of the study that lead to that approval. XX Adaptyx presented early clinical data supporting a wearable sensor that continuously measures cortisol levels. The device successfully tracked cortisol changes during both controlled testing and overnight monitoring in first-in-human studies. Company leaders say cortisol plays a major role in conditions including diabetes, hypertension, and depression. The technology uses synthetic DNA-based molecular switches to generate real-time readings.   XX Biolinq shared new clinical findings for its Shine continuous glucose monitoring system. The needle-free device combines glucose monitoring with activity and sleep tracking .The system received FDA clearance in 2025. They're also looking at measuring lactate through the sensor. XX Long-time T1D advocate Kent Schnakenberg died last week. Schnakenberg was known in his community for using his love of bicycling to raise awareness of Type 1 diabetes. He also advocated for improving the lives of those living with the disease. Inspired by his niece, Michelle, who was diagnosed with juvenile diabetes when she was 13 years old, since 2014 he has traveled around the country cycling thousands of miles, speaking to hundreds and hundreds of kids and raising Money. According to Schnakenberg's family, he suffered a head trauma incident in his home on Wednesday. I spoke to Kent years ago – I believe the first year of the podcast. A sad loss but wonderful to see so many tributes and memories posted on social media in the last few days. https://diabetes-connections.com/john-costik-co-creator-of-nightscout-team-schnak/ https://www.wibw.com/2026/06/12/team-schnak-founder-kent-schnakenberg-passes-away/ XX And finally. Alexander Zverev (ts-ver-uhv) won the French Open, his first Grand Slam title. He lives with type 1, he paused a couple of time to check his blood sugar. He was diagnosed at age 4 and partners with Medtronic. "Becoming a professional tennis player was always my dream," Zverev shared in an article posted by Medtronic. "Early on, I was told that competing at the highest level with diabetes was impossible — but my family and I refused to accept that. That's why I'm partnering with Medtronic Diabetes: I want every person with diabetes to feel empowered to live the life they want." He also has a foundation committed to children with type 1 diabetes. Among other things, the life-saving insulin and other essential drugs are provided – also in developing countries." https://www.mensjournal.com/news/alexander-zverev-diabetes-wins-french-open-2026-medical-condition

Vista Equity Partners CEO Robert Smith joins after the firm just launched a new enterprise AI inference cloud at Intel Computex. Then, the CEO of Honeywell Aerospace discusses the company's growth strategy ahead of its spinoff. Later, the CEO of Medtronic joins to break down the health tech company's latest quarter. Plus, Sara Eisen joins from Jerusalem after speaking with Israel's Prime Minister Benjamin Netanyahu. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcripts: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We'll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We've got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind's afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients.   The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: "Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option." Lots more to come on this – we're working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. https://www.massdevice.com/mannkind-fda-approval-inhaled-insulin-children/ XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it's such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They're calling this Libre Duo and Libre Duo 10 Day, and it's designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes   XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery  with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic.   Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action.   The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling.   Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said.   People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX   Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics' interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association's Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet's patch pumps on the market. It would have a 200-unit insulin reservoir.   Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall.   https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it's coverage list – with it's Caremark PBM. They also added Foundayo, Lilly's obesity pill. CVS had dropped Lilly's Zepound last summer but kept competitor Wegovy. It'll be back at Caremark October first. All three of the nation's largest pharmacy ⁠benefit managers ​now cover Lilly's full obesity medicine portfolio. https://www.reuters.com/legal/litigation/cvs-brings-back-coverage-lillys-obesity-drug-zepbound-2026-05-28/   More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers.   Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). "Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence," the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women.   Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea.   While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. "Tidepool has always focused on making diabetes data more accessible and actionable," said Brandon Arbiter, CEO. "We're excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters."   Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool's existing EHR integration capabilities.   Direct Connect is part of Tidepool's ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes.   The feature is now available in the Connection Hub of the Epic Showroom.   https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX